However, in this study using two different HR-positive, HER2-negative cell lines resistant to PAL or ABE, the resistant cells developed cross-resistance to the other CDK4/6 inhibitor but not to several chemotherapeutic agents commonly used for the treatment of advanced breast cancer resistant to CDK4/6 inhibitors. Here, ERBB2 is linked to breast cancer.